NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
"We welcome Dr. Sherman to our Board of Directors," said Charles J. Link, Jr, MD, Chairman and Chief Executive Officer. “His extensive experience in both clinical development and corporate management further strengthens our Board and represents a valuable addition to NewLink Genetics.”
Dr. Sherman is currently Executive Vice President and Chief Medical Officer of
Prior to joining Acceleron, Dr. Sherman was Senior Vice President and Chief Medical Officer at
Dr. Sherman received an S.B. degree in Chemistry (Phi Beta Kappa) from the
Dr. Sherman serves on the
“I look forward to joining NewLink Genetics and working with its Board and management team on indoximod development which has shown promising early data," said Dr. Sherman.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "guidance," "upcoming," "will," "plan," "anticipate," "approximate," "expect," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about NewLink Genetics' financial guidance for 2018; results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; NewLink Genetics' future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended
Director of Investor Relations
617-374-8800, ext. 105
A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/cc694a7c-0e15-4539-ad40-47b2e77e2461
Source: NewLink Genetics Corporation